HS3ST2 and gastric cancer: Hsa-mir-100, hsa-mir-145 and hsa-mir-125b-2 are tumour suppressors of gastric cancer and regulate potential signalling pathways for gastric cancer cell proliferation, apoptosis and metastasis; for example, hsa-mir-100 antagonism increases the expression level of HS3ST2, the target gene of hsa-mir-100, leading to the activation of the Notch apoptotic pathway in tumour cells to suppress the development of gastric cancer [50].